June 2 (Reuters) - Viatris Inc VTRS.O:
VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 LYNX-2 TRIAL OF MR-142 IN KERATOREFRACTIVE PATIENTS WITH VISUAL DISTURBANCES UNDER MESOPIC, LOW-CONTRAST CONDITIONS
VIATRIS INC - MR-142 ACHIEVED PRIMARY ENDPOINT OF ≥15-LETTER GAIN IN MLCVA
VIATRIS INC - NO EVIDENCE OF TACHYPHYLAXIS OBSERVED OVER 6-WEEK PERIOD
VIATRIS INC - RESULTS SHOW FUNCTIONAL BENEFIT IN TREATING NIGHT DRIVING IMPAIRMENT
Source text: ID:nPn7bLWjsa
Further company coverage: VTRS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.